CNIPA.AI

Company patentsInnovative medicines and biopharmaceuticals

COMPANY PATENT INTELLIGENCE

Pfizer Patent Portfolio Analysis

Explore medicines, formulations and related technologies through publications attributed to selected Pfizer legal entities.

Partial name or date coverage · counts are lower boundsData as of 2026-11-17Data scope
Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Source search matches
998
Published 2025-01-01 — 2025-12-31 · Source Google Patents
Applicant names included in these statistics
PFIZER · PFIZER INC
Publication dates collected
Not recorded in this snapshot
Reviewed names not covered
PFIZER INC.
Compare with other companies
Collected patent publications

≥998docs

83 per month · peak 2025-03 (155)

Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.

01Key figures

Applications
960
By application number; publication and grant count once
Invention
449
47% of applications
Utility model
0
0% of applications
Patent families
392
By the source family ID
Green technology
—
The source has no CPC codes
Concentration
0.99HHI
Sum of squared field shares; higher is more concentrated

INSIGHT 01Fact

87%

87% of applications are in Pharmaceuticals

812 applications in this field, 760 of them in IPC A61K — the main axis of the portfolio.

Method: Field applications ÷ applications with IPC

02Technology landscape

934 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.

  • Electrical engineering
  • Instruments
  • Chemistry
  • Mechanical engineering
Explore reviewed themes, sample patents and evidence

03Rhythm

Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.

This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.

Cells count publications only within the collected names and dates. Missing periods are not shown; the company portfolio is incomplete.
Technology field25-0125-0225-0325-0425-0525-0625-0725-0825-0925-1025-1125-12
Pharmaceuticals5467137698368754254845753
Organic fine chemistry212362293926281819242622
Biotechnology243557283122261624311415
Medical technology435332734340
Chemical engineering330200100012
Analysis of biological materials012010201021
Macromolecular chemistry, polymers211102001100
Computer technology301100100030

Filing years of the collected applications

Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.

  • 20111
  • 20122
  • 20136
  • 20149
  • 201525
  • 201663
  • 201735
  • 201815
  • 201976
  • 202042
  • 202157
  • 202256
  • 2023234
  • 2024199
  • 2025140Publication lag may still apply

Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.

Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.

04Strategy profile

Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.

Concentration

0.99
0.001.43

Position 5 of 26 published companies.

Method: Sum of squared field shares

Utility model share

0%
0%33%

Position 9 of 26 published companies.

Method: Utility model documents ÷ all documents

Green technology share

—

The source has no CPC codes, so this cannot be computed.

Method: Documents with CPC Y02 ÷ documents with CPC

Manufacturing and inspection share

2.3%
0%50%

Position 16 of 26 published companies.

Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications

05Collaboration

Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.

CTXT PTY LTD39Other co-applicant · relationship unverified
ARVINAS OPERATIONS INC13Other co-applicant · relationship unverified
ALLOGENE THERAPEUTICS INC11Other co-applicant · relationship unverified
ASTELLAS PHARMA INC11Other co-applicant · relationship unverified
BRISTOL MYERS SQUIBB CO9Other co-applicant · relationship unverified
GENENTECH INC9Other co-applicant · relationship unverified
MERCK PATENT GMBH9Other co-applicant · relationship unverified
UNIV CALIFORNIA8Other co-applicant · relationship unverified
BRIGHAM & WOMENS HOSPITAL INC7Other co-applicant · relationship unverified
HOFFMANN LA ROCHE7Other co-applicant · relationship unverified

Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.

Review the entity list

06Entities and scope

Entity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.

Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.

Showing 1 of 1 entities

Pfizer Inc.

Primary entityVerifiedSome names covered
Names collected in this snapshot
PFIZER · PFIZER INC
Names outside this snapshot
Pfizer Inc.
Recorded relationship dates
Not recorded — Not recorded

原始申请人示例将 PFIZER 与 PFIZER INC 对应到 Pfizer Inc.。未纳入 Seagen、惠氏及其他子公司独立名下文献。

Review evidence

Relationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.

07Observations

Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.

Technology themes and evidence

Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.

Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.

Showing 2 sample patents · 0 linked observations

Reading samples

Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.

US20250000960A1

Polynucleotide compositions and uses thereof

The abstract describes RNA encoding an E. coli FimH antigen and lipid-nanoparticle formulations. Claim 1 specifically requires a FimH-encoding open reading frame and a 5′ untranslated region with at least 90% identity to one of the listed sequences. Lipid nanoparticles appear in the abstract but are not a required element of this claim.

Bibliography and claim evidence
Applicants
Pfizer Inc.
Application date
2024-06-11
Publication date
2025-01-02
English summary of cited claim evidence
US20250000960A1, claim 1 (reading note, not a verbatim quotation)The abstract describes RNA encoding an E. coli FimH antigen and lipid-nanoparticle formulations. Claim 1 specifically requires a FimH-encoding open reading frame and a 5′ untranslated region with at least 90% identity to one of the listed sequences. Lipid nanoparticles appear in the abstract but are not a required element of this claim.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

US20250009864A1

Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

The abstract concerns pneumococcal capsular glycoconjugates. Claims 1–31 are marked cancelled in this publication, so the reading uses claim 32: a kit containing two immunogenic compositions, each including at least one glycoconjugate from its respective listed serotype group. The two at-least-one requirements do not require every listed serotype.

Bibliography and claim evidence
Applicants
Pfizer Inc.
Application date
2024-03-19
Publication date
2025-01-09
English summary of cited claim evidence
US20250009864A1, claim 32 (reading note, not a verbatim quotation)The abstract concerns pneumococcal capsular glycoconjugates. Claims 1–31 are marked cancelled in this publication, so the reading uses claim 32: a kit containing two immunogenic compositions, each including at least one glycoconjugate from its respective listed serotype group. The two at-least-one requirements do not require every listed serotype.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

08Publication jurisdictions

39 publication offices · 998 documents

Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.

  1. USUnited States128
  2. EPEuropean Patent Office publication121
  3. MXMexico108
  4. WOPCT international publication91
  5. AUAustralia66
  6. TWTaiwan57
  7. CNChina56
  8. ILIsrael54
Show 31 more jurisdictions
  1. KRSouth Korea52
  2. JPJapan28
  3. ARArgentina27
  4. ESSpain25
  5. PEPeru20
  6. COColombia13
  7. DKDenmark13
  8. FIFinland11
  9. NZNew Zealand11
  10. PTPortugal11
  11. CACanada8
  12. CRCosta Rica8
  13. HRCroatia8
  14. SISlovenia8
  15. HUHungary7
  16. LTLithuania7
  17. MDMoldova7
  18. PLPoland7
  19. RSSerbia7
  20. DODominican Republic6
  21. MAMorocco6
  22. CLChile5
  23. LULuxembourg4
  24. MYMalaysia4
  25. ZASouth Africa4
  26. FRFrance2
  27. NONorway2
  28. PYParaguay2
  29. UAUkraine2
  30. CYCyprus1
  31. SASaudi Arabia1

09Documents

998 published documentsNewest first
  1. US12485157B2

    Invention grant

    Method of treating COVID-19

    PFIZER

    Pharmaceuticals

    2025-12-02
  2. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

    PFIZER / BISHWA RAJ BHETUWAL / Kaushik Dutta / JIANXIN GU / SUNAYANA KAPIL / JIN HWAN KIM / JUSTIN KEITH MORAN / SUDDHAM SINGH / YUYING YANG

    Pharmaceuticals

    2025-12-01
  3. Methods of treating hepatic-only metastatic uveal melanoma

    IDEAYA BIOSCIENCES INC / PFIZER / MAURER MATTHEW ANTHONY / HATA YUJIRO / OQUIGLEY MICHAEL GABRIEL

    Pharmaceuticals

    2025-12-01
  4. Compuestos de pirido[4,3-d]pirimidina

    PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-30
  5. Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos

    PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-30
  6. Antagonistas del receptor de polipéptido insulinotrópico dependiente de glucosa y usos de estos

    PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-30
  7. Benzisoxazole sulfonamide derivatives

    PFIZER / CTXT PTY LTD

    Organic fine chemistryPharmaceuticals

    2025-11-30
  8. CN121038808A

    Invention publication

    Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

    PFIZER

    Pharmaceuticals

    2025-11-28
  9. CN121038810A

    Invention publication

    Combination vaccine against coronavirus infection, influenza infection and/or RSV infection

    BIOTECH EUROPE S A / PFIZER

    Pharmaceuticals

    2025-11-28
  10. CN121039104A

    Invention publication

    Substituted indazole propionic acid derivative compounds and their use as AMPK activators

    PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-28
  11. JP2025175010A

    Invention publication

    Anti-EDB antibodies and antibody-drug conjugates

    PFIZER

    BiotechnologyPharmaceuticals

    2025-11-28
  12. DLL3 targeting chimeric antigen receptors and binding agents

    ALLOGENE THERAPEUTICS INC / PFIZER

    BiotechnologyPharmaceuticals

    2025-11-27
  13. Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof

    PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-27
  14. WO2025245032A1

    Invention publication

    Methods of manufacturing a bifunctional compound

    ARVINAS OPERATIONS INC / PFIZER

    Organic fine chemistry

    2025-11-27
  15. WO2025245200A1

    Invention publication

    Ponsegromab for use in treating cachexia in cancer patients

    PFIZER

    BiotechnologyPharmaceuticals

    2025-11-27
  16. Composición farmacéutica en solución acuosa

    PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-26
  17. EP4444303A4

    Invention publication

    Combination therapy comprising a pkc inhibitor and a c-met inhibitor

    IDEAYA BIOSCIENCES INC / PFIZER

    Organic fine chemistryPharmaceuticals

    2025-11-26
  18. EP4651889A1

    Invention publication

    Vaccines against respiratory diseases

    PFIZER

    BiotechnologyPharmaceuticals

    2025-11-26
  19. EP4651890A1

    Invention publication

    Immunogenic compositions and methods of inducing an immune response against varicella zoster virus

    PFIZER

    Pharmaceuticals

    2025-11-26
  20. Benzisoxazole sulfonamide derivatives

    PFIZER / CTXT PTY LTD

    Organic fine chemistryPharmaceuticals

    2025-11-26

Titles come from the source bibliography. Select a number to read the full document on this site.

Drafting a patent in this field?

Upload your invention disclosure and get an editable draft that follows CNIPA practice.

Start drafting

10Method and sources

Counting units

Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.

Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.

Entity scope

These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.

Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Applicant names included in these statistics
PFIZER · PFIZER INC
Reviewed names not covered
PFIZER INC.
Current entity configuration and review evidence

The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.

Pfizer Inc.

Configured aliases: PFIZER · PFIZER INC

Original review note: 原始申请人示例将 PFIZER 与 PFIZER INC 对应到 Pfizer Inc.。未纳入 Seagen、惠氏及其他子公司独立名下文献。

Review evidence

Data sources

  • Google Patents · PartialPublished 2025-01-01 to 2025-12-31 · retrieved 2026-11-17 · 998 included · 0 out of scopeSource and terms

Found a wrong attribution or number? Tell us